Carnitine Injection (L-Carnitine)

Adult administration

1. Primary and secondary carnitine deficiency Myocardial metabolic disorder due to ischemic heart disease: angina pectoris, acute myocardial infarction Adults: Administer 2~3 grams of L-carnitine daily, divided into 2~3 doses, by intramuscular or intravenous injection. Adjust the dose as needed according to age and symptoms. 2. Treatment of carnitine deficiency in patients with end-stage renal disease receiving hemodialysis Initially, administer 10~20 milligrams/kilogram intravenously over 2~3 minutes at the end of each hemodialysis session. The dose may be adjusted according to the plasma L-carnitine level before hemodialysis.

This medication comes in an ampoule form, which carries the risk of glass fragments being mixed in during use. Therefore, great care should be taken when breaking the container, especially when administering to children or the elderly. It should not be administered to patients with allergic reactions or hypersensitivity to this drug. Temporary side effects such as nausea, vomiting, abdominal pain, diarrhea, and changes in body odor may occur when using this medication. Gastritis may occur rarely, and patients with a history of seizures may experience seizures more frequently or severely, so caution is advised. Various side effects have been reported in patients undergoing chronic hemodialysis, including abdominal pain, allergic reactions, asthma, back pain, chest pain, fever, flu-like symptoms, infection, and pain at the injection site. It may affect the cardiovascular system, leading to cardiac issues such as arrhythmias or ventricular fibrillation, and symptoms like changes in blood pressure, palpitations, and tachycardia may occur. Gastrointestinal side effects may include loss of appetite, constipation, diarrhea, dyspepsia, gastrointestinal disorders, nausea, and vomiting. Side effects have also been reported in various body systems including the endocrine, blood and lymphatic system, metabolic and nutritional problems, musculoskeletal system, nervous system, respiratory system, skin, and special senses, and urinary system, so if any unusual symptoms occur, immediate consultation with healthcare professionals is necessary. The safety of this drug during pregnancy has not been established; therefore, women who are pregnant or may become pregnant should use it only when the benefits of treatment outweigh the risks. For breastfeeding women, it is uncertain whether this drug is transferred to breast milk, but as many drugs do pass into breast milk, caution is advised during lactation.

• Nausea
• vomiting
• abdominal pain
• diarrhea
• body odor
• gastritis
• seizures
• abdominal pain
• accidental injury
• allergic reactions

This drug may be sensitive to light; therefore, it should be stored in a light-resistant container. Additionally, it is recommended to store the drug at room temperature, avoiding excessively hot or cold places.

Appearance

A clear colorless to pale yellow solution in a brown transparent ampoule injection.

Package unit

1 ampoule (5 mL) x 10, (for export) 1 ampoule (5 mL) x 5, 10